Schimmelpennink Evert B. 4

What Happened

• Evert B. Schimmelpennink, a member of Contineum Therapeutics' board of directors, received a grant of options to acquire 19,000 shares of the company's Class A common stock on June 26, 2026. The Form 4 lists the transaction as an award (transaction code A) and shows $0.00 in the price column, indicating a derivative option grant rather than a cash purchase. No immediate cash value was exchanged in the filing.

Key Details

• Transaction date: 2026-06-26 (Form 4 filed the same date).
• Transaction type/code: Grant/Award (A) — stock options (derivative).
• Shares/units: Options covering 19,000 shares.
• Price reported on Form 4: $0.00 (reflects grant; not an exercise price).
• Vesting: Options vest in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting of stockholders, subject to continuous service (per footnote).
• Shares owned after transaction: Not specified in the Form 4 filing.
• Filing timeliness: Reported same day as the transaction (timely).

Context

• This is a routine non-employee director compensation grant under Contineum’s 2024 Equity Incentive Plan and the company’s Non-Employee Director Compensation Program (automatic annual grant for continuing non-employee directors). As an unexercised option award, it does not represent an immediate purchase or sale of shares. Retail investors should view this as standard board compensation rather than a direct insider buy or sell signal.